Izencitinib induction treatment in patients with moderately-to-severely-active Crohn's Disease: A phase 2 double-blind, randomized, placebo-controlled study

被引：0
|
作者：
Schreiber, S. [1 ]
Reinisch, W. [2 ]
Nguyen, D. [3 ]
Guerin, T. [4 ]
Kierkus, J. [5 ]
Rozpondek, P. [6 ]
Bourdet, D. [3 ]
Abhyankar, B. [7 ]
Peyrin-Biroulet, L. [8 ]
机构：
[1] Univ Kiel, Univ Hosp Schleswig Holstein, Dept Internal Med I, Kiel, Germany
[2] Med Univ Vienna, Dept Internal Med III, Vienna, Austria
[3] Theravance Biopharma Inc, Res & Dev, San Francisco, CA USA
[4] Theravance Biopharma Ireland Ltd, Res & Dev, Dublin, Ireland
[5] Childrens Mem Hlth Inst, Dept Gastroenterol, Warsaw, Poland
[6] Krakow Med Ctr, Krakow, Poland
[7] Theravance Biopharma Ireland Ltd, Clin Dev, Dublin, Ireland
[8] Univ Lorraine, Nancy Univ Hosp, Dept Gastroenterol, Vandoeuvre Les Nancy, France
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P375
引用
收藏
页码：505 / 507
页数：3
相关论文
共 50 条
  • [21] DHEA treatment of Alzheimer's disease - A randomized, double-blind, placebo-controlled study
    Wolkowitz, OM
    Kramer, JH
    Reus, VI
    Costa, MM
    Yaffe, K
    Walton, P
    Raskind, M
    Peskind, E
    Newhouse, P
    Sack, D
    De Souza, E
    Sadowsky, C
    Roberts, E
    NEUROLOGY, 2003, 60 (07) : 1071 - 1076
  • [22] Methotrexate in Crohn's disease: Results of a randomized, double-blind, placebo-controlled trial
    Arora, S
    Katkov, W
    Cooley, J
    Kemp, JA
    Johnston, DE
    Schapiro, RH
    Podolsky, D
    HEPATO-GASTROENTEROLOGY, 1999, 46 (27) : 1724 - 1729
  • [23] Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohn's disease
    Sands, B. E.
    Gasink, C.
    Gao, L-L
    Blank, M. A.
    Johanns, J.
    Guzzo, C.
    Chiou, C-F
    Sandborn, W. J.
    Hanauer, S. B.
    Targan, S.
    Rutgeerts, P.
    Ghosh, S.
    de Villiers, W.
    Panaccione, R.
    Greenberg, G.
    Schreiber, S.
    Lichtiger, S.
    Feagan, B. G.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S24 - S24
  • [24] Efficacy and safety of an oral tyrosine kinase 2 inhibitor VTX958 in moderately to severely active Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 trial
    Danese, S.
    Jairath, V
    Sands, B. E.
    Schreiber, S.
    Panaccione, R.
    D'Haens, G.
    Lindstrom, B.
    Liu, K.
    Sandborn, W.
    Rubin, D. T.
    Peyrin-Biroulet, L.
    Vermeire, S.
    Naik, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1852 - i1853
  • [25] APREMILAST FOR ACTIVE ULCERATIVE COLITIS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Danese, Silvio
    Neurath, Markus
    Kopon, Adam
    Zakko, Salam F.
    Simmons, Timothy C.
    Fogel, Ronald P.
    Maccarone, Judy
    Zhan, Xiaojiang
    Usiskin, Keith
    Chitkara, Denesh
    GASTROENTEROLOGY, 2018, 154 (06) : S167 - S167
  • [26] Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
    Vermeire, Severine
    Lakatos, Peter L.
    Ritter, Timothy
    Hanauer, Stephen
    Bressler, Brian
    Khanna, Reena
    Isaacs, Kim
    Shah, Saumin
    Kadva, Alysha
    Tyrrell, Helen
    Oh, Young S.
    Tole, Swati
    Chai, Akiko
    Pulley, Jennifer
    Eden, Christopher
    Zhang, Wenhui
    Feagan, Brian G.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (01): : 28 - 37
  • [27] Fontolizumab in Moderate to Severe Crohn's Disease: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study
    Reinisch, Walter
    de Villiers, Williem
    Bene, Laszlo
    Simon, Laszlo
    Racz, Istvan
    Katz, Seymour
    Altorjay, Istvan
    Feagan, Brian
    Riff, Dennis
    Bernstein, Charles N.
    Hommes, Daniel
    Rutgeerts, Paul
    Cortot, Antoine
    Gaspari, Michael
    Cheng, May
    Pearce, Tillman
    Sands, Bruce E.
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (02) : 233 - 242
  • [28] Ciprofloxacin for the Prevention of Postoperative Recurrence in Patients with Crohn's Disease: A Randomized, Double-blind, Placebo-controlled Pilot Study
    Herfarth, Hans H.
    Katz, Jeffry A.
    Hanauer, Stephen B.
    Sandborn, William J.
    Loftus, Edward V., Jr.
    Sands, Bruce E.
    Galanko, Joseph A.
    Walkup, Dolly
    Isaacs, Kim L.
    Martin, Christopher F.
    Sandler, Robert S.
    Sartor, Ryan B.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (05) : 1073 - 1079
  • [29] Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
    Zou, Hejian
    Wan, Weiguo
    Xue, Yu
    Sun, Lingyun
    Zhang, Ning
    Chen, Haiying
    Shi, Xiaofei
    Liu, Shengyun
    Chen, Lin
    Ma, Xinmei
    Wei, Hua
    Jiang, Zhenyu
    Li, Xiaomei
    Fan, Hongtao
    Li, Hongbin
    Li, Jingyang
    Wu, Rui
    Shi, Guixiu
    Zhu, Jing
    Kong, Xiaodan
    Lu, Yuewu
    Cui, Xiaojing
    Zheng, Qianning
    Bai, Xiaoyan
    Dong, Guangchao
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5240 - 5242
  • [30] A PHASE 1/2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE INDUCTION OF CLINICAL RESPONSE AND REMISSION BY QBECO IN SUBJECTS WITH MODERATE TO SEVERE CROHN'S DISEASE
    Gunn, Hal
    Sutcliffe, Simon
    Pankovich, Jim
    Chen, Jenny M.
    Vandermeirsch, Gillian
    Thompson, Darby
    Fedorak, Richard N.
    Panaccione, Remo
    Axler, Jeffrey L.
    Bressler, Brian
    GASTROENTEROLOGY, 2017, 152 (05) : S600 - S600
12345